Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBio-Rad Laboratories Inc

Bio-Rad Laboratories Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
381.57 USD 12.57 ( 3.41%)
Last update at 2026-11-06T21:00:00Z
VOLUME
273157
Market Cap
8253.82M
P/E
10.98

Momentum Score

…

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
363.59
Low
384.62
High
52 Week Price Range
211.43
Low
343.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bio-Rad Laboratories makes life-science research instruments, reagents and consumables and provides clinical diagnostic systems to academic, biotech and clinical laboratories worldwide. Long-term growth may be supported by secular demand for genomics and diagnostics, recurring consumables sales and ongoing product introductions, and the company appears positioned with a diversified product mix and an installed base that provides recurring revenue.

Key risks include exposure to research funding and testing-volume cycles, competitive pressure, regulatory and reimbursement uncertainty in diagnostics, and execution risk on new products and acquisitions; investors should monitor these factors.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
369.00
Dividend Yield
-
Revenue TTM
2583.20M
Revenue Per Share
94.69
Gross Profit TTM
1343.60M
Debt / Equity
0.21
ROE
10.84%
Net Debt
999.20M
ROCE
2.69%
Diluted EPS TTM
27.85

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 995.50M -2342.50M -850.10M -4704.27M 5438.15M
Net income 759.90M -1844.20M -637.32M -3627.53M 4245.90M
Selling general administrative 844.30M 814.00M 846.80M 827.83M 879.57M
Gross profit 1343.60M 1378.90M 1426.95M 1567.33M 1640.66M
Reconciled depreciation 165.40M 151.60M 144.20M 137.30M 133.80M
Ebit 270.50M -2293.60M -800.70M 482.62M 489.43M
Ebitda 475.90M -2142.00M -654.80M 664.49M 650.01M
Depreciation and amortization 205.40M 151.60M 145.90M 181.87M 160.58M
Non operating income net other - - - 44.78M 24.02M
Operating income 270.50M 269.00M 337.80M 482.62M 489.43M
Other operating expenses 2317.10M 2297.50M 2333.40M 2319.63M 2433.11M
Interest expense 49.00M 48.90M 49.44M 38.11M 1.55M
Tax provision 235.60M -498.30M -27.92M -1076.74M 1192.25M
Interest income 95.50M 82.00M 96.40M 58.00M 4921.94M
Net interest income 46.50M 33.10M 47.64M 19.89M -1.55M
Income tax expense 235.60M -498.30M -212.78M -1076.74M 1192.25M
Total revenue 2583.20M 2566.50M 2671.26M 2802.25M 2922.55M
Total operating expenses 1077.50M 1109.90M 1089.10M 1084.71M 1151.23M
Cost of revenue 1239.60M 1187.60M 1244.32M 1234.92M 1281.88M
Total other income expense net 725.00M -2611.50M -1187.90M -5186.89M 4948.72M
Net income from continuing ops 759.90M -1844.20M -159.30M -3627.53M 4245.90M
Net income applicable to common shares 759.90M -1844.20M -637.32M -3627.53M 4245.90M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10576.50M 9364.10M 12299.07M 13501.67M 17775.79M
Intangible assets 174.30M 293.60M 320.48M 332.15M 253.94M
Other current assets 150.30M 153.30M 171.65M 147.78M 117.83M
Total liab 3122.90M 2794.80M 3557.94M 3886.41M 4108.66M
Total stockholder equity 7453.60M 6569.30M 8741.13M 9615.25M 13667.13M
Deferred long term liab - - - 1770.48M 3059.08M
Other current liab 313.50M 271.40M 302.04M 186.20M 210.67M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings 8176.30M 7416.40M 9260.63M 9898.20M 13507.24M
Other liab - - - 1966.39M 3417.21M
Good will 579.80M 410.50M 413.60M 406.49M 347.34M
Other assets 102.70M 2511.80M - 94.60M 0.08M
Cash 531.80M 488.10M 403.97M 434.21M 470.78M
Cash and equivalents 529.80M 488.10M - 434.21M 470.78M
Total current liabilities 517.00M 467.80M 522.80M 568.71M 680.94M
Current deferred revenue - - 35759.00M 52.21M 50.85M
Net debt 999.20M 886.60M 1001.63M 763.97M -459.78M
Short term debt 37.90M 42.90M 40.38M 0.47M 0.49M
Short long term debt 1.30M 1.20M 0.49M 0.47M 0.49M
Short long term debt total 1531.00M 1374.70M 1405.44M 1198.18M 11.00M
Other stockholder equity -533.60M -308.90M -183.46M 183.87M 335.44M
Property plant equipment 709.90M 688.60M - 498.61M 695.75M
Total current assets 2906.20M 3030.30M 3048.33M 3157.98M 1989.09M
Long term investments 6103.60M 4839.20M 7698.07M 8830.89M 14387.01M
Net tangible assets - - - 9208.76M 13065.85M
Short term investments 1010.90M 1176.40M 1203.33M 1362.02M 404.69M
Net receivables 472.50M 452.50M 489.02M 494.64M 423.54M
Long term debt 1203.00M 1200.40M 1199.05M 1197.72M 10.51M
Inventory 740.70M 760.00M 780.52M 719.32M 572.24M
Accounts payable 129.00M 122.30M 144.62M 329.83M 418.93M
Accumulated other comprehensive income -189.10M -538.20M -336.04M -466.82M -175.55M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - 9898.20M 13507.24M
Treasury stock - - - -263.59M -106.29M
Non currrent assets other 102.30M 101.90M 94.45M -1770386.40M -3058977.33M
Non current assets total 7670.30M 6333.80M 9250.74M 10343.69M 15786.71M
Capital lease obligations 181.80M 173.10M 205.86M 189.93M 212.37M
Long term debt total 1201.70M 1200.40M - 1197.72M 10.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 186.30M -160.20M -110.54M -994.21M -538.17M
Change to liabilities - - - -1335.80M 1152.20M
Total cashflows from investing activities -189.70M -160.20M - -1207.59M -784.44M
Net borrowings -0.50M -0.40M - 1185.71M -3.02M
Total cash from financing activities -283.20M -218.80M -425.65M 973.58M -55.43M
Change to operating activities - - - -26.80M 13.93M
Net income 759.90M -1844.20M -637.32M -3627.53M 4245.90M
Change in cash 40.30M 85.40M -30.18M -36.59M -195.98M
Begin period cash flow 489.80M 404.40M 434.54M 471.13M 667.12M
End period cash flow 532.20M 489.80M 404.37M 434.54M 471.13M
Total cash from operating activities 532.20M 455.20M 374.94M 194.45M 656.52M
Depreciation 205.40M 151.60M 192.40M 137.30M 133.80M
Other cashflows from investing activities 793.60M -23.30M - -100.60M -658.92M
Dividends paid - - 100101.00M 68184.00M 35282.00M
Change to inventory 68.90M 8.50M -46.30M -158.80M 46.10M
Change to account receivables 19.60M 16.20M 11.40M -87.40M -20.40M
Sale purchase of stock -295.50M -203.60M -428.73M -215.68M -50.00M
Other cashflows from financing activities -3.00M -14.80M 3.55M -212.13M -2.41M
Change to netincome - - - 5254.73M -3776.38M
Capital expenditures 157.60M 189.00M 156.68M 114.16M 120.80M
Change receivables - - - 68.18M 35.28M
Cash flows other operating - - - 126.26M 621.24M
Exchange rate changes - - - - -12.64M
Cash and cash equivalents changes - - - -39.57M -195.98M
Change in working capital 275.60M -620.80M -127.63M -407.04M 13.93M
Stock based compensation 58.00M 62.30M 61.30M 60.90M 51.20M
Other non cash items -879.20M 2706.30M 1078.60M 5272.42M -3737.11M
Free cash flow 374.60M 266.20M 218.26M 80.29M 535.72M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BIO
Bio-Rad Laboratories Inc		 12.57
3.41%		 381.57 10.98 30.21 3.20 1.11 3.08 6.58
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

1000 Alfred Nobel Drive, Hercules, CA, United States, 94547

510 724 7000

https://www.bio-rad.com

7450

Name Title Year Born
Mr. Norman D. Schwartz Chairman, CEO & Pres 1950
Mr. Ilan Daskal Exec. VP & CFO 1966
Dr. Andrew J. Last Ph.D. Exec. VP & COO 1960
Mr. Michael Crowley Exec. VP of Global Commercial Operations 1962
Ms. Dara Grantham Wright Exec. VP & Pres of Clinical Diagnostics Group 1976
Mr. Ajit Ramalingam Sr. VP & Chief Accounting Officer 1973
Mr. Yong Chung VP of Investor Relations NA
Mr. Timothy S. Ernst Exec. VP, Gen. Counsel & Sec. 1960
Colleen Corey Sr. VP of Global HR NA
Lee Boyd Sr. VP of Global Commercial Operations - Asia Pacific NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…